

117TH CONGRESS
2D SESSION

S. 3553

To review domestic biopharmaceutical manufacturing capabilities in order to improve public health and medical preparedness and response capabilities and domestic biopharmaceutical manufacturing capabilities.

IN THE SENATE OF THE UNITED STATES

FEBRUARY 2, 2022

Mr. RUBIO (for himself and Mr. COONS) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions

A BILL

To review domestic biopharmaceutical manufacturing capabilities in order to improve public health and medical preparedness and response capabilities and domestic biopharmaceutical manufacturing capabilities.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

3 **SECTION 1. SHORT TITLE.**

4 This Act may be cited as the “Agility in Manufac-
5 turing Preparedness Act”.

1 **SEC. 2. REVIEW OF DOMESTIC BIOPHARMACEUTICAL MAN-**
2 **UFACTURING CAPABILITIES.**

3 (a) IN GENERAL.—The Secretary of Health and
4 Human Services (referred to in this section as the “Sec-
5 retary”), in cooperation with the Director of the Bio-
6 medical Advanced Research and Development Authority,
7 shall seek to enter into an agreement with the National
8 Institute for Innovation in Manufacturing Biopharma-
9 ceuticals to perform the services described in subsection
10 (b).

11 (b) REVIEW AND RECOMMENDATIONS.—Under an
12 agreement described in subsection (a) between the Sec-
13 retary, the Director of the Biomedical Advanced Research
14 and Development Authority, and the National Institute for
15 Innovation in Manufacturing Biopharmaceuticals, the Na-
16 tional Institute for Innovation in Manufacturing Bio-
17 pharmaceuticals shall—

18 (1) review current domestic biopharmaceutical
19 manufacturing capacity at the Department of
20 Health and Human Services and its adaptability to
21 various threats;

22 (2) draft recommendations for developing, dem-
23 onstrating, deploying, and advancing new domestic
24 biopharmaceutical manufacturing technologies that
25 address gaps identified under paragraph (1) and
26 align Federal technologies with technologies avail-

1 able to the private sector, including through the new
2 BioMAP initiative of the Biomedical Advanced Re-
3 search and Development Authority; and

4 (3) identify other opportunities and priorities to
5 improve the United States public health and medical
6 preparedness and response capabilities and domestic
7 biopharmaceutical manufacturing capabilities.

○